CEO of Dotmatics Discusses Artificial Intelligence for Medical Research
Thomas Swalla, CEO of Dotmatics, discusses on Good Morning Chicago how artificial intelligence is transforming medical research by improving medical decisions and treatments, while Dotmatics leverages AI to reduce drug discovery costs.
Thomas Swalla joins Good Morning Chicago to discuss trends in how artificial intelligence is impacting medical decisions and treatments on a broad scale.
Learn More About Dotmatics
Meet with a product expert to see how Dotmatics uses AI technologies to drive down the cost of drug discovery.
Related
CBS News: How AI Is Accelerating Safer, More Personalized Drug Discovery
In a CBS News interview, Dotmatics VP Phil Mounteney explains how their internally developed AI models accelerate drug discovery by analyzing early-phase research data to shorten development cycles, reduce costs, and deliver safer, personalized therapies while maintaining data privacy.
KRON TV: AI in Medicine From Research Assistant to Predictive Partner
In a KRON-TV interview, Dotmatics VP Phil Mounteney discusses how AI is evolving from a research assistant automating data tasks to a predictive partner that accelerates drug discovery by identifying new targets, designing molecules, and enabling personalized therapies, ultimately reducing costs and time to market while expanding patient access to safer, tailored medicines.
ABC News: How AI is Transforming Drug Discovery
Christian Olsen, VP of Biologics at Dotmatics, explains in an ABC News interview how AI is transforming pharmaceutical R&D by accelerating drug target identification and high-throughput screening, thereby significantly reducing the time and cost of drug discovery and enabling breakthroughs in diseases like cancer, diabetes, cardiovascular conditions, and neurology.
NBC Las Vegas: AI is Accelerating Drug Discovery and Vaccine Development
In an NBC Las Vegas interview, Phil Mounteney, VP of Science and Technology at Dotmatics, explains how AI is transforming drug discovery and vaccine development by accelerating research timelines, reducing costs, enhancing drug safety through advanced data analysis, and optimizing development pipelines for faster and more efficient medical breakthroughs post-COVID.
NBC News: How AI is Transforming Drug Discovery
In an NBC News segment, Alister Campbell, VP of Dotmatics, explains how the company leverages AI to analyze large datasets, predict effective drug compounds, and streamline fragmented data systems and manual workflows, thereby accelerating and improving the efficiency of drug discovery.
NBC Louisiana: How AI is Accelerating Drug Discovery
In an NBC Louisiana feature, Dotmatics’ VP Phil Mounteney explained how AI is revolutionizing drug discovery by significantly reducing development time from up to ten years to potentially half, enhancing efficiency in analyzing vast data sets while ensuring data privacy by keeping sensitive information secure and in-house.